Gbesemete, Diane, Ramasamy, Maheshi N., Ibrahim, Muktar, Hill, Alison R., Raud, Lucy, Ferreira, Daniela M., Guy, Jonathan, Dale, Adam P., Laver, Jay R., Coutinho, Tyween, Faust, Saul N., Reed, Thomas A.N., Babbage, Gavin, Weissfeld, Lisa, Lang, Wei, Locht, Camille, Samal, Vivek, Goldstein, Peter, Solovay, Ken, Rubin, Keith, Noviello, Stephanie and Read, Robert C. (2025) Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis. The Lancet Microbe, 6 (12), [101211]. (doi:10.1016/j.lanmic.2025.101211).
Record type:
Article
Abstract
Background
Pertussis is a severe respiratory disease caused by Bordetella pertussis. Although vaccines prevent disease for a limited duration, they do not prevent infection and transmission. We aimed to assess the safety and efficacy of BPZE1 at preventing or substantially reducing colonisation by virulent B pertussis using a robust controlled human infection model.
MethodsThis randomised, placebo-controlled, phase 2b trial was conducted at University Hospital Southampton and University of Oxford in the UK. Eligible participants were healthy adults aged 18–50 years, who complied with the protocol, refrained from smoking and nasal sprays, and were fully vaccinated against SARS-CoV-2. Exclusion criteria were pertussis vaccination or illness (<5 years), baseline anti-pertussis toxin serum IgG (>20 International Units [IU]/mL) or anti-pertactin serum IgG (>30 IU/mL) concentrations, and a positive SARS-CoV-2 test. Participants were randomly assigned (1:1), using permuted blocks with a block size of four, to receive an intranasal dose of 109 colony-forming units (CFU) of BPZE1 or placebo (lyophilised buffer) and were challenged 60–120 days later with 105 CFU virulent B pertussis. Masked staff administered the study vaccine. Nasal mucosal secretion and blood samples were collected. The primary outcome was negative B pertussis cultures of nasal washes at days 9, 11, and 14 after virulent challenge in the modified intention-to-treat (mITT; defined as all participants randomly assigned to treatment who were vaccinated, challenged, and had at least one culture result at day 9, 11, or 14 post-challenge) and per protocol adequate inoculum populations (defined as all participants in the mITT population who received a challenge inoculum equal to or higher than the target (≥0·5 × 105 CFU; sensitivity analysis). This trial is registered with ClinicalTrials.gov, NCT05461131.
FindingsBetween June 23, 2022, and Oct 26, 2023, 141 participants were assessed for eligibility, of whom 88 were ineligible and 53 were randomly assigned (26 to the BPZE1 group and 27 to the placebo group). 26 (49%) participants were male and 27 (51%) were female, with a mean age of 30·42 years (SD 8·49). Participants self-identified as White (42 [79%]), Black (six [11%]), or Asian (five [9%]). Five (9%) participants did not receive virulent challenge and two (4%) were lost to follow-up before virulent challenge. 46 (87%) participants received virulent challenge at 60–120 days (24 in the BPZE1 group vs 22 in the placebo group). One in the BPZE1 group withdrew consent and one in the placebo group was not evaluable due to COVID-19. 44 (83%) completed the challenge trial unit stay (23 [88%] vs 21 [78%]). 24 (92%) participants in the BPZE1 group and 21 (78%) in the placebo group were included in the mITT population. In the mITT population, the number of participants with no detectable colonisation on days 9, 11, and 14 post-challenge was higher in the BPZE1 group (14 [58%; 95% CI 39–76] of 24 vs seven [33%; 17–55] of 21 in the placebo group; p=0·091). Four (17%) in the BPZE1 group and five (24%) in the placebo group received a lower challenge dose than the target. In the per protocol adequate inoculum population, 12 (60%; 39–78) of 20 in the BPZE1 group and four (25%; 10–50) of 16 in the placebo group had no detectable colonisation by B pertussis B1917 on days 9, 11, and 14 post-challenge (p=0·033). Most participants reported at least one solicited adverse event during the 7 days after vaccination (22 [85%] of 26 in the BPZE1 group vs 22 [81%] of 27 in the placebo group), which were mostly mild (grade 1) in severity. Unsolicited adverse events were reported in similar frequency in the BPZE1 and placebo groups during the 28 days after vaccination (seven [27%] of 26 vs nine [33%] of 27). No serious adverse events or discontinuations due to adverse events were reported during the trial.
InterpretationIntranasal BPZE1 vaccination prevented or substantially reduced infection after challenge with virulent B pertussis and is an attractive vaccine candidate. Given the favourable safety profile, large phase 3 trials are warranted to confirm these initial findings.
Text
PIIS2666524725001399
- Version of Record
Available under License Creative Commons Attribution Non-commercial No Derivatives.
Download (394kB)
More information
e-pub ahead of print date: 1 December 2025
Additional Information:
Publisher Copyright:
© 2025 The Author(s).
Identifiers
Local EPrints ID: 509183
URI: http://eprints.soton.ac.uk/id/eprint/509183
ISSN: 2666-5247
PURE UUID: 13de9830-f1b3-403f-8eb3-7a7470a742bf
Catalogue record
Date deposited: 12 Feb 2026 17:40
Last modified: 13 Feb 2026 02:53
Export record
Altmetrics
Contributors
Author:
Diane Gbesemete
Author:
Maheshi N. Ramasamy
Author:
Muktar Ibrahim
Author:
Lucy Raud
Author:
Daniela M. Ferreira
Author:
Jonathan Guy
Author:
Adam P. Dale
Author:
Tyween Coutinho
Author:
Thomas A.N. Reed
Author:
Gavin Babbage
Author:
Lisa Weissfeld
Author:
Wei Lang
Author:
Camille Locht
Author:
Vivek Samal
Author:
Peter Goldstein
Author:
Ken Solovay
Author:
Keith Rubin
Author:
Stephanie Noviello
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.